Check 35,000+ stocks against 26 valuation models and 37 quality factors

Ayurcann Holdings Corp (AYURF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Ayurcann Holdings Corp $0.00, price $0.00, upside +1.7%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? No
Add to watchlist

Healthcare · US

Thin data Sep 27, 2026

Ayurcann Holdings Corp

AYURF · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $0.0003 · Fairly valued (+1.7%)

!Quality 45/100

!Mixed Growth (revenue 3y +41.1 %/yr)

!Loss-making · -13.9% net margin (TTM)

✓Negative equity (buybacks among others) · generates free cash flow

!Trails peers (1/6)

!Narrow moat 5/100

!Evidence only low, so the estimate is less certain

!Weak on future: 11 out of 100

26 models, one by oneBear $0.0003 to bull $0.0003 Growth analysisrevenue history, year by year Quality 45/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Ayurcann Holdings Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range $0.0002 – $0.1935 · fair‑value band $0.0003 – $0.0003 · the $0.0003 price screens below the $0.0003 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow Ayurcann Holdings in your weekly email

Every Wednesday you see whether Ayurcann Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Ayurcann Holdings Corp. provides post-harvest outsourcing solutions to licensed cannabis producers in Canada. The company offers extraction, processing, and co-manufacturing of pharma grade cannabis to produce various derivative cannabis products in the medical and recreational markets. It also manufactures and distributes cannabis products.

Stock analysis

Ayurcann Holdings Corp (AYURF) currently trades at $0.0003, while our model-based Fair Value estimate is $0.0003, so the stock looks roughly fairly valued today (gap 1.6%).

Valuation

Bull case: the Growth DCF group reads highest at a median of $0.0003 per share, and 1 of the 6 models we run sit above the $0.0003 price.

Bear case: the Multiples group reads lowest at $0.0001, and 5 of the 6 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.0003 (bear) to $0.0003 (bull), the price of $0.0003 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Ayurcann Holdings Corp reported revenue of C$31.1M in FY2025 versus C$7.6M in FY2021, a compound +42.1%/yr. Reported net income was −C$3.5M in FY2025.

Key figures

Market cap $389K · EPS (TTM) $−0.0200 · Net margin −11.2% · Return on equity −264% · Return on assets (EBIT) −14.0% · Operating margin −11.3% · Revenue (TTM) C$31.3M · Revenue growth (YoY) +2.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).

What moves the price

The share trades about 99% below its 52-week high and 50% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 2%, AYURF screens cheaper than that median.

Fair Value models

Bear $0.0003 Fair Value $0.0003 Bull $0.0003

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $0.0002 $0.0003 $0.0006 74

Growth DCF $0.0002 $0.0004 $0.0006 73

5Y Revenue Exit $0.0001 $0.0002 $0.0004 68

All 6 models by family

DCF Models

FCF DCF $0.0002 $0.0003 $0.0006 74

5Y Revenue Exit $0.0001 $0.0002 $0.0004 68

10Y Revenue Exit $0.0002 $0.0003 $0.0004 65

Multiples

EV/Revenue $0.0001 $0.0001 $0.0002 53

Growth DCF

Growth DCF $0.0002 $0.0004 $0.0006 73

Rev-Margin DCF $0.0001 $0.0003 $0.0005 67

Open the full fair value analysis →

Notify me when AYURF reaches fair value

Put AYURF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 45/100

Of which business quality 48 · Market factors (momentum, volatility) 11

Profitability 50

Margins and returns on capital today

Quality Growth 69

Are margins and returns improving?

Cashflow 59

Earnings quality: real cash, not paper profit

Fin. Strength 17

Balance sheet, leverage, solvency risk

Investment 67

Disciplined investing over empire-building

Low Volatility 36

Calm price path (market factor)

Momentum 0

Price trend over the last 3–12 months (market factor)

52W Momentum 0

Distance to the 52-week high (market factor)

Net Issuance 40

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 50/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+23.7%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+41.1%

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

28.3% (2021) → −7.9% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

Watch AYURF, get fair value alerts →

Compare Ayurcann Holdings Corp with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks

Beats the industry median on 1/6 measures

Overall it trails its industry peers.

Valuation

Quality Score 45 · Below median

Fair Value upside +1.7% · Above median

Profitability

Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Return on assets −16.6% · Bottom 25%

Net margin (TTM) −13.9% · Bottom 25%

Operating margin (TTM) −11.3% · Bottom 25%

Growth and dividend

Revenue growth 2.1% · Below median

Balance sheet

Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)36 · sector 17

FUTURE (revenue growth)11 · sector 24

PAST (return on equity)0 · sector 27

HEALTH (low debt)0 · sector 96

DIVIDEND (yield)0 · sector 30

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€134.45	€108.94	−19%
Takeda Pharmaceutical Company TAK	$18.90	$11.45	−39%
Teva Pharmaceutical Industries Limited TEVA	$39.31	$20.88	−47%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,852	₹1,979	+7%
Galderma Group GALD	CHF 163.00	CHF 110.32	−32%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥44.86	¥49.35	+10%
Haleon plc HLN	$9.26	$8.49	−8%
Sandoz Group SDZ	CHF 71.16	CHF 40.32	−43%
Zoetis Inc ZTS	$70.30	$110.50	+57%
Divi's Laboratories Limited DIVISLAB	₹9,620	₹1,871	−81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ayurcann Holdings Corp · Fair Value
$0.0003 +2%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/AYURF" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Ayurcann Holdings Corp · Fair Value</span><br><b style="font-size:20px">$0.0003</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+2%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Ayurcann Holdings Corp Fair Value". https://www.fairvalue-calculator.com/stock/AYURF

Frequently asked questions

Is Ayurcann Holdings Corp (AYURF) overvalued or undervalued?

As of Sep 27, 2026, our model estimates a fair value of $0.0003 versus the last price from Sep 25, 2026 of $0.0003, about +2% upside (fairly valued).

What is the fair value of AYURF?

Our model-based fair value for Ayurcann Holdings Corp is $0.0003 (as of Sep 27, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0003.

What is the quality score of AYURF?

Ayurcann Holdings Corp has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Ayurcann Holdings Corp (AYURF)?

Our model-based price target is the fair value of $0.0003 (as of Sep 27, 2026) from 6 valuation models. Cautious scenario $0.0003, optimistic scenario $0.0003. It is a calculation from audited fundamentals, not an analyst target.

What is the Ayurcann Holdings Corp stock forecast for 2026?

Our models put fair value at $0.0003, about +2% upside versus the last price from Sep 25, 2026 of $0.0003 (fairly valued). Cautious scenario $0.0003, optimistic scenario $0.0003. The calculation is refreshed regularly with new filings.

What is the revenue of Ayurcann Holdings Corp (AYURF)?

Ayurcann Holdings Corp reported trailing-twelve-month revenue of about C$31.3M (latest available figure, as of Sep 27, 2026).

What is the intrinsic value of Ayurcann Holdings Corp (AYURF)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ayurcann Holdings Corp it is $0.0003 per share (as of Sep 27, 2026), against a price of $0.0003. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).

Is Ayurcann Holdings Corp stock overvalued or undervalued in 2026?

As of Sep 27, 2026, AYURF trades below its calculated fair value: price $0.0003, fair value $0.0003, a gap of about +2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of AYURF?

No. The price is what the market pays today ($0.0003); the fair value is what the company's own numbers justify ($0.0003). For Ayurcann Holdings Corp the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.

How much is Ayurcann Holdings Corp worth?

The market values Ayurcann Holdings Corp at about $389K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0003; our models calculate a fair value of $0.0003 per share.

What do the bullish and bearish scenarios say about AYURF?

Our models span a range for Ayurcann Holdings Corp: cautious scenario $0.0003, base $0.0003, optimistic $0.0003 per share (as of Sep 27, 2026, price $0.0003). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Ayurcann Holdings Corp (AYURF)?

Balance-sheet figures for Ayurcann Holdings Corp (as of Sep 27, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 45/100, which measures business quality independently of the share price.

How far is AYURF from its 52-week high?

Ayurcann Holdings Corp trades at $0.0003, about 99% below its 52-week high of $0.0340 and 50% above the low of $0.0002 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0003 is for.

Which stocks are comparable to Ayurcann Holdings Corp?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Ayurcann Holdings Corp stock attractive at the current price?

The data as of Sep 27, 2026: price $0.0003, calculated fair value $0.0003 (+2%), Quality Score 45/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of AYURF calculated?

We run Ayurcann Holdings Corp through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0003, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Ayurcann Holdings Corp currently trades 2 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Ayurcann Holdings Corp (AYURF)?

The latest price we hold is from Sep 25, 2026 and stands at $0.0003. Our model-based fair value is $0.0003, about +2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Ayurcann Holdings Corp right now?

The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.0003 to $0.0003), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Ayurcann Holdings Corp

How large is the market capitalisation of Ayurcann Holdings Corp (AYURF)?

The market capitalisation of Ayurcann Holdings Corp is $389K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What are the earnings per share of Ayurcann Holdings Corp (AYURF)?

Earnings per share at Ayurcann Holdings Corp are $−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Ayurcann Holdings Corp (AYURF)?

The net margin of Ayurcann Holdings Corp is −11.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Ayurcann Holdings Corp (AYURF)?

The return on equity (ROE) of Ayurcann Holdings Corp is −264% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Ayurcann Holdings Corp (AYURF)?

On an EBIT basis the return on assets of Ayurcann Holdings Corp is −14.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Ayurcann Holdings Corp (AYURF)?

The operating margin of Ayurcann Holdings Corp is −11.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Ayurcann Holdings Corp (AYURF)?

Revenue at Ayurcann Holdings Corp is growing +2.1% versus a year earlier (3y avg +41.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How much free cash flow does Ayurcann Holdings Corp (AYURF) generate?

The free cash flow of Ayurcann Holdings Corp is C$2.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

Free · no account needed

Watch Ayurcann Holdings Corp in the live analysis

One click puts Ayurcann Holdings Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.